Immune Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
November 16, 2020 at 11:15 am EST
Share
Immune Therapeutics, Inc. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced operating loss was USD 131,033 compared to USD 389,202 a year ago. Net income was USD 4.094 million compared to net loss of USD 941,485 a year ago. For the nine months, operating loss was USD 544,341 compared to USD 1.483 million a year ago. Net income was USD 2.497 million compared to net loss of USD 2.475 million a year ago.
Biostax Corp. is a developer and marketer of pharmaceutical, biotechnology, and MedTech products. The Company has partnerships in the fields of autoimmunity and immune restoration and are able to deliver solutions today for people that are living with autoimmunity, chronic inflammation, infection, and cancer. Its internal and partner programs comprised of JKB-122, an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) that has demonstrated anti-fibrotic, immuno-modulating, and anti-inflammatory activities in preclinical models; Lodonal, is a once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS), and LDN, which is a compound formula that is purported to provide immune-modulating benefits that include cancer, pain, autoimmune, and anti-aging.
BIOSTAX CORP. 
